Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250718 · ClinicalTrials.gov registry record · Phase 2
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00250718 is a Phase 2 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 17 participants.
The verdict
NCT00250718, a Phase 2 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies. 1.2 To determine the toxicity profile of the above regimen in this patient population. 1.3 Evaluate the effect of low dose administration of chemotherapy on angiogenesis, and correlate this with tumor responses.
Interventions
- DRUG Rituximab
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Levofloxacin
- DRUG VP-16
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250718
The ClinicalTrials.gov registry entry for NCT00250718 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT00250718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00250718 about?
NCT00250718 is a clinical study titled "Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach". 1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies. 1.2 To determine the toxicity profile of the above regimen in this patient population. 1.3 Evaluate the effect of low dos...
What is the current status of trial NCT00250718?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2004-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00250718?
The interventions under investigation include: Rituximab (DRUG), Dexamethasone (DRUG), Vincristine (DRUG), Levofloxacin (DRUG), VP-16 (DRUG).
Who is sponsoring clinical trial NCT00250718?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.